<DOC>
	<DOCNO>NCT03090113</DOCNO>
	<brief_summary>This randomize , double blind , placebo-controlled , parallel , multicenter research order evaluate effect Shuxuetong injection prevention symptomatic asymptomatic new cerebral infarction within 10 day . Subgroup study：Evaluate role advance diagnostic technique identify potential cause Embolic Stroke Undetermined Source ( ESUS ) .</brief_summary>
	<brief_title>Shuxuetong Prevention Recurrence Acute Cerebrovascular Events With Embolism</brief_title>
	<detailed_description>Shuxuetong injection Placebo injection 10days . About 2416 patient randomize 80 center China 20 subgroup study center . Face face interview baseline , 10 day , 90 day .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<criteria>Inclusion criterion 1 . More equal 18 year old less 80 year old ; 2 . Acute ischemic stroke , brain magnetic resonance imaging show non lacunar infarction ( subcortical infarction less equal 1.5 cm ) ; 3 . Firstever stroke ; 4 . Onset within 72 hour ; 5 . Patients family member willing sign inform consent . Exclusion criteria 1 . Intracranial hemorrhage : cerebral hemorrhage , subarachnoid hemorrhage , etc . ; 2 . Transient ischemic attack ; 3 . Lacunar infarction ; 4 . Clear diagnosis cause ischemic stroke ( arterial dissection , arteritis , vasospasm , etc . ) ; 5 . ASPECTS less equal 7 posterior circulation ASPECTS le equal 7； 6. modify Rankin Scale ( mRS ) equal 2 stroke ; 7 . Cumulative usage traditional Chinese medicine activate blood circulation 3 time onsite , include limited : Danhong , Xueshuantong , Xuesaitong , Ginkgo biloba , sodium ozagrel , Salvia miltiorrhiza , ligustrazine , Erigeron breviscapus , etc ; 8 . Chronic liver disease , liver kidney dysfunction , lift alanine aminotransferase ( 3 time great ULN ) , lift serum creatinine ( 2 time great ULN ) ; 9 . History Coagulopathy , systemic bleeding , thrombocytopenia neutropenia ; 10 . Blood pressure less equal 90/60 mmHg blood pressure equal 220/120 mmHg treatment ; 11 . Serious heart lung disease , researcher deem suitable study ; 12 . Patients atrial fibrillation schedule likely receive anticoagulant therapy unfractionated heparin low molecular weight heparin within 2 week randomization 13 . Life expectancy le 3 month fulfill study reason ; 14 . Known allergy ingredient drug , allergy history food drug ; 15 . Women childbearing age negative Pregnancy test result refuse take effective contraceptive measure , pregnant woman lactate woman ; 16 . Joined clinical study last 30 day ; 17 . Unable understand and/or comply study procedure and/or followup study due mental illness , cognitive emotional disorder . Subgroup Exclusion Criteria 1 . History atrial fibrillation 2 . Atrial fibrillation 12lead electrocardiogram ( ECG ) ; 3 . Heart rate monitoring ( dynamic electrocardiogram telemetry ) 20 hour detect atrial fibrillation 6 minute ; 4 . Intracardiac thrombosis thoracic esophageal echocardiography ; 5 . Occlusion proximal vessel infarction 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Embolic Stroke</keyword>
	<keyword>Shuxuetong</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Symptomatic New Cerebral Infarction</keyword>
	<keyword>Asymptomatic New Cerebral Infarction</keyword>
</DOC>